Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML
O'Hare, Thomas, Pollock, Roy, Stoffregen, Eric P., Keats, Jeffrey A., Abdullah, Omar M., Moseson, Erika M., Rivera, Victor M., Tang, Hao, Metcalf, Chester A., Bohacek, Regine S., Wang, Yihan, Sundaramoorthi, Raji, Shakespeare, William C., Dalgarno, David, Clackson, Tim, Sawyer, Tomi K., Deininger, Michael W., Druker, Brian J.
Published in Blood (15.10.2004)
Published in Blood (15.10.2004)
Get full text
Journal Article
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes
Summy, Justin M, Trevino, Jose G, Lesslie, Donald P, Baker, Cheryl H, Shakespeare, William C, Wang, Yihan, Sundaramoorthi, Raji, Metcalf, 3rd, Chester A, Keats, Jeffrey A, Sawyer, Tomi K, Gallick, Gary E
Published in Molecular cancer therapeutics (01.12.2005)
Published in Molecular cancer therapeutics (01.12.2005)
Get full text
Journal Article
Abstract B011: Synergistic activity of tazemetostat in combination with androgen signaling inhibitors in preclinical models of prostate cancer demonstrates potential for clinical expansion
Motwani, Vinny, Brach, Dorothy, Pantano, Chloe, Estanek, Vania, Keats, Jeffrey A., Dransfield, Daniel T., Raimondi, Alejandra
Published in Molecular cancer therapeutics (01.12.2019)
Published in Molecular cancer therapeutics (01.12.2019)
Get full text
Journal Article
Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton's tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma
Keats, Jeffrey A., Lee, Arleide, Cunniff, Jeremy C., Chen, Weiqing, Mehovic, Revonda, Estanek, Vania, Markwood, Crag, Tang, Cuyue, Dransfield, Daniel T., Gibaja, Veronica, Raimondi, Alejandra
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Abstract 1944: Tazemetostat displays synergistic antiproliferative activity with backbone therapies in preclinical models of AT/RT and MRT
Klaus, Christine R., Keats, Jeffrey A., Smith, Jesse J., Chesworth, Richard, Copeland, Robert A., Ribich, Scott, Raimondi, Alejandra
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Published in Cancer research (Chicago, Ill.) (01.07.2017)
Get full text
Journal Article
Abstract B82: Pinometostat (EPZ-5676) enhances the antiproliferative activity of MAP kinase pathway inhibitors in MLL -rearranged leukemia cell lines
Raimondi, Alejandra, Klaus, Christine R., Keats, Jeffrey A., Daigle, Scott R., Copeland, Robert A., DiMartino, Jorge, Smith, Jesse J., Blakemore, Stephen J.
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Abstract 5383: DOT1L inhibitor EPZ-5676 synergizes with cytarabine and azacitidine in preclinical models of MLL-rearranged leukemia
Klaus, Christine R., Daigle, Scott R., Chopra, Vivek, Keats, Jeffrey A., Campbell, Carly T., Iwanowicz, Dorothy, Olhava, Edward J., Scott, Margaret P., Pollock, Roy M., Copeland, Robert A., Smith, Jesse J., DiMartino, Jorge, Blakemore, Stephen J., Raimondi, Alejandra
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Published in Cancer research (Chicago, Ill.) (01.08.2015)
Get full text
Journal Article